Clearside Biomedical (CLSD) announces that two subgroup analyses were presented from the ODYSSEY Phase 2b clinical trial at the Angiogenesis, ...
RBC Capital analyst Paul Treiber maintained a Buy rating on Celestica (CLS – Research Report) today and set a price target of $160.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback